Supriya Lifescience Limited, a prominent player in the pharmaceutical industry, has achieved a significant milestone with the receipt of a Good Manufacturing Practices (GMP) certificate from the World Health Organization (WHO) for its Ambernath facility. This certification marks a crucial step in the company's global expansion strategy, enabling it to conduct production and distribution operations on a worldwide scale.

WHO GMP Certification Details

The WHO conducted a GMP audit for Inhalation Dosages at Supriya Lifescience's Ambernath facility on September 2, 2025. Following the successful completion of the audit, the WHO issued the GMP certificate, declaring the facility compliant with Good Manufacturing Practices standards.

Implications of the Certification

The WHO-GMP certification brings several key advantages to Supriya Lifescience:

• Global Production Capability: The company can now carry out production at the Ambernath facility for international markets.
• Expanded Distribution Rights: Supriya Lifescience is now eligible to distribute its products in Rest of the World markets and other eligible territories.
• Quality Assurance: The certification serves as a testament to the high-quality manufacturing standards maintained at the Ambernath facility.

Company's Perspective

In a regulatory filing to the stock exchanges, Supriya Lifescience stated, "We do not expect this development to have any material impact on the current business operations or existing supplies from this facility." While the immediate financial impact may be limited, the certification positions the company for potential long-term growth in international markets.

About Supriya Lifescience Limited

Supriya Lifescience Limited is a recognized Export House with its corporate office located in Mumbai, Maharashtra. The company operates a factory in the Lote Parshuram Industrial Area, demonstrating its commitment to pharmaceutical manufacturing excellence.

This WHO GMP certification for the Ambernath facility reinforces Supriya Lifescience's position in the global pharmaceutical landscape and may open doors to new opportunities in international markets. As the company continues to expand its global footprint, stakeholders will be keen to observe how this certification translates into business growth and market penetration in the coming years.

Supriya Lifescience , a prominent player in the pharmaceutical industry, has unveiled an ambitious growth strategy aimed at significantly boosting its financial performance and market presence over the next few years.

Targeting Robust Financial Growth

The company has set its sights on achieving EBITDA margins of 33-35% by the fiscal year 2026 (FY26). This target is coupled with an aggressive year-on-year revenue growth projection of 20%, with the ultimate goal of reaching Rs 1,000.00 crore in revenue by FY27.

Strategic Initiatives for Expansion

Executive Chairman Satish Waman Wagh outlined several key strategies to drive this growth:

1. Product Innovation: The company plans to launch 3-4 new products annually, demonstrating a commitment to expanding its product portfolio.

2. US Market Entry: Supriya Lifescience is making a strategic push into the United States market, aiming to challenge Chinese competitors and capture market share in one of the world's largest pharmaceutical markets.

3. New Product Launches: The company has already launched a new anaesthetic product, targeting a market valued at $300.00 million. This move showcases Supriya's ability to identify and enter lucrative market segments.

4. Potential Blockbuster in Pipeline: Discussions are underway with multinational corporations for a product that has a $7.00 billion market potential, indicating the company's ambition to compete on a global scale.

Capital Expenditure and Infrastructure Development

To support its growth plans, Supriya Lifescience has outlined a significant capital expenditure strategy:

• For the current year, the company plans to invest Rs 65.00-70.00 crore in capital expenditure.
• Over the next three years, a total of Rs 200.00 crore has been allocated for the development of a new site in Patalganga, Maharashtra.

Competitive Edge and Market Focus

Supriya Lifescience is positioning itself strategically in the global pharmaceutical landscape:

• The company is focusing on regulated markets, ensuring compliance with stringent quality standards.
• It maintains USFDA-compliant manufacturing facilities, which is crucial for entering and succeeding in the US market.
• Supriya emphasizes backwards integration in its operations, a strategy aimed at maintaining cost efficiencies to effectively compete against Chinese manufacturers.

This comprehensive approach, combining financial targets, product innovation, market expansion, and operational efficiency, positions Supriya Lifescience for potential strong growth in the coming years. The company's focus on high-value markets and products, coupled with its investment in infrastructure and compliance, suggests a well-rounded strategy to capture market share and drive profitability in the competitive pharmaceutical industry.